• Today, I'm going to use AI to value Pfizer on my own terms.
  Of course, I don't have the right knowledge and all the conditions are my own assumptions, so please take this as an exercise.
  Let's start by writing about Pfizer, the hottest stock during the coronavirus.
• In the complex world of stock market investments, tools like the Dividend Discount Model (DDM) provide investors with a structured way to value stocks, particularly those known for paying dividends. Today, we're focusing on Pfizer, a pharmaceutical titan, and how the DDM sheds light on its investment potential

Understanding the Dividend Discount Model

The DDM is a straightforward yet powerful tool in financial analysis. It values a stock by summing up all expected future dividend payments, discounted back to their present value. The model hinges on three key parameters:

1. The upcoming annual dividend.
2. The expected growth rate of these dividends.
3. The required rate of return (or discount rate).

The formula is as simple as it is elegant:

Price = D1 / (r - g)

Where D1 is the next year's expected dividend, r is the required return, and g is the dividend growth rate.

Pfizer's Case Study

• Let's apply the DDM to Pfizer, using a projected annual dividend of $1.67, a growth rate of 2.7%, and a discount rate of 6%. The intrinsic value calculated stands at about $50.61 per share. However, in the investing world, we embrace caution with a 10% margin of safety, adjusting the target buy price to around $45.55.

Contemplating a Hypothetical Scenario

• Imagine a situation where Pfizer's sales are halved. The immediate reaction might be a reevaluation of the stock value. However, if Pfizer maintains its dividend, the DDM valuation initially seems unchanged. But, is this a sustainable scenario?

Sustainability and Market Sentiment

• Maintaining dividends despite a 50% sales cut raises questions about long-term sustainability. It's crucial to consider the company's overall financial health and the market's perception of this drastic change. A significant sales drop typically increases the risk profile, potentially necessitating a higher discount rate and lowering the valuation.

Real-World Implications

• The real value of Pfizer’s stock in such a scenario would reflect more than just its dividend policy. It would also consider the company's ability to bounce back, manage cash flows effectively, and maintain investor confidence.

Concluding Thoughts

• While our DDM analysis suggests a certain intrinsic value for Pfizer, it's a snapshot based on current data and assumptions. The model's simplicity is both a strength and a limitation, as it doesn't account for unforeseen market dynamics or internal corporate changes. Investors should use DDM as one of many tools in their arsenal, combining it with a thorough analysis of financial health, market trends, and risk assessment.

Investing is as much an art as it is a science. Models like DDM provide structure, but the unpredictable nature of the market always adds an element of surprise.

I wrote it in English for the sake of learning English.
I hope you'll forgive me if there's any awkwardness.

pfe-20231001 (sec.gov)